Metropolis Healthcare Limited — Investor Meet, 14-08-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Metropolis Healthcare's Q1 FY26 earnings call highlights strong performance. Group revenue jumped 23.2% YoY, with organic growth at 13.2%. Organic EBITDA margin stood at 24.7%, and PAT increased 21.2% to Rs. 46.2 Cr. Core Diagnostics is now EBITDA positive, targeting high single-digit margins. Acquisitions are smoothly integrating, generating key synergies. MHL acquired Ambika Diagnostics for Rs. 17 Cr, expected to boost earnings immediately. The company is accelerating organic growth via specialty diagnostics (+16%) and TruHealth (+22%), expanding its network by 80 new collection centers. Management is confident for FY26, anticipating significant growth and margin improvements.